- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00311454
Quaternium-15, Use Test
April 4, 2006 updated by: Mekos Laboratories AS
An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15
The study is required by the FDA as part of a post-marketing commitment.
The purpose of the study is to compare the reactivity of the TRUE Test quaternium-15 patch and a real use exposure.The subjects will wear the patch test for 48 hours and reading will be performed day 3 or 4. The use test will be applied from day 3 or 4 and untill reaction appears.
Reactions from respectively TRUE Test and use test will be compared using the McNemar Change Test.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment
10
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gentofte, Denmark, 2900
- Amtssygehuset i Gentofte
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sensitivity to quaternium-15
- Age more than 18 years
Exclusion Criteria:
- Topical or systemic treatment with corticosteroids or immunosuppresives.
- Treatment with UV-light
- Widespread active dermatitis or dermatitis on test area
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Study Registration Dates
First Submitted
April 4, 2006
First Submitted That Met QC Criteria
April 4, 2006
First Posted (ESTIMATE)
April 6, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
April 6, 2006
Last Update Submitted That Met QC Criteria
April 4, 2006
Last Verified
April 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mekos 05 UseQ 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Contact Dermatitis Towards Quaternium-15
-
Hospices Civils de LyonRecruitingContact Dermatitis | Contact Dermatitis Irritant | Contact Dermatitis, AllergicFrance
-
Ramsay Générale de SantéInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingEczema | Allergic Contact Eczema NosFrance, Belgium
-
Herlev and Gentofte HospitalKarolinska InstitutetCompleted
-
Herlev and Gentofte HospitalGöteborg University; University of Copenhagen; Sahlgrenska University Hospital...CompletedAllergic Contact Dermatitis Due to CosmeticsDenmark, Sweden
-
Andreas Syggros Hospital of Venereal and Dermatological...RecruitingAllergic Contact DermatitisGreece
-
Herlev and Gentofte HospitalCompletedAllergic Contact DermatitisDenmark
-
Rockefeller UniversityWashington University School of Medicine; Tel Aviv UniversityCompleted
-
Hadassah Medical OrganizationMorria Biopharmaceuticals PLCCompletedAllergic Contact DermatitisIsrael
-
Mekos Laboratories ASCompleted
-
Hospices Civils de LyonNot yet recruitingAllergic Contact Dermatitis